RIPK1 and bacterial infectious disease: Our work expands on that by Kitur et al. who showed inhibition of RIP1 conferred a beneficial effect against S. aureus. Specifically, we show that blocking of RIP1 or MLKL, but not RIP3 inhibitors, confers a beneficial effect against S. marcescens. As such, two independent studies now suggest that necroptosis inhibitors may serve as an adjunct therapy for diverse bacterial infections caused by PFT-producing pathogens [7].